StockData
Humacyte, Inc. logo

Humacyte, Inc. (HUMA) income statement

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.50−0.04 (-7.27%)

Close on Nov 17, 2026Market cap $139.18MP/E –Yield –

Humacyte, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
-494.6%
Operating margin
-5240.8%
Net margin
-4560.8%
Return on equity, FY2025
164.8%

Financial strength

Current ratio
6.21
Debt to equity
–
Debt to assets
–
Cash to current liabilities
534.5%

Valuation

P/E ratio
–
Price to sales
65.62
Price to book
4.45
Dividend yield
–

See a number that looks wrong?